Quarterly ResultMay 6, 2026, 04:02 PM
MannKind Q1 Revenue +15% to $90.2M; Afrezza, Furoscix PDUFA Dates Set
AI Summary
MannKind Corporation reported Q1 2026 total revenues of $90.2 million, a 15% increase year-over-year, driven by higher royalties and Furoscix sales. Despite the revenue growth, the company posted a net loss of $(16.6) million, compared to a net income of $13.2 million in Q1 2025, due to increased operating expenses. Key upcoming milestones include PDUFA dates for Afrezza pediatric indication (May 29, 2026) and Furoscix ReadyFlow Autoinjector (July 26, 2026), alongside pipeline advancements for Nintedanib DPI and a collaboration with United Therapeutics for Ralinepag DPI.
Key Highlights
- Q1 2026 total revenues grew 15% to $90.2 million.
- Q1 2026 net loss was $(16.6) million vs. $13.2 million net income in Q1 2025.
- Afrezza pediatric indication PDUFA date set for May 29, 2026.
- Furoscix ReadyFlow Autoinjector PDUFA date set for July 26, 2026.
- Nintedanib DPI (MNKD-201) advancing to Phase 2; INFLO-2 trial starts Q2 2026.
- Ralinepag DPI (MNKD-1501) collaboration with United Therapeutics, received $5M.
- Settled $36.3M senior convertible notes for $35.5M cash and shares.
- Cash, cash equivalents, and investments totaled $134 million.